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Abstract
 
Mast cells are believed to be involved in the pathophysiology of heart failure, but their precise
role in the process is unknown. This study examined the role of mast cells in the progression of
heart failure, using mast cell-deficient (WBB6F1-W/W
 
v
 
) mice and their congenic controls
(wild-type [WT] mice). Systolic pressure overload was produced by banding of the abdominal
aorta, and cardiac function was monitored over 15 wk. At 4 wk after aortic constriction, car-
diac hypertrophy with preserved left ventricular performance (compensated hypertrophy) was
observed in both W/W
 
v
 
 and WT mice. Thereafter, left ventricular performance gradually de-
creased in WT mice, and pulmonary congestion became apparent at 15 wk (decompensated
hypertrophy). In contrast, decompensation of cardiac function did not occur in W/W
 
v
 
 mice;
left ventricular performance was preserved throughout, and pulmonary congestion was not
observed. Perivascular fibrosis and upregulation of mast cell chymase were all less apparent in
 
W/W
 
v
 
 mice. Treatment with tranilast, a mast cell–stabilizing agent, also prevented the evolu-
tion from compensated hypertrophy to heart failure. These observations suggest that mast cells
play a critical role in the progression of heart failure. Stabilization of mast cells may represent a
new approach in the management of heart failure.
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Introduction
 
When the heart is exposed to pressure overload, cardiac hy-
pertrophy develops to preserve its function by normalizing
chamber wall stress (1). If mechanical overload persists, the
hypertrophied heart dilates and its contractile function de-
creases, resulting in congestive heart failure (1). The mech-
anism of transition from compensated hypertrophy to heart
failure has not been clarified (2).
Mast cells are found in the human heart (3), and have
 
been implicated in cardiovascular diseases (4,
 
 
 
5). They
were increased in both hypertrophied (5) and failing hearts
(6). However, their role in the pathophysiology of cardiac
hypertrophy and failure is unclear. We have recently ob-
served that mast cells cause apoptosis of cardiac myocytes
and proliferation of nonmyocytes in vitro (7). As loss of
cardiac myocytes and proliferation of nonmyocytes both
result in cardiac dysfunction (1), we hypothesized that
myocardial mast cells may be implicated in the progression
of heart failure.
This study was performed to examine whether mast cells
play a role in the evolution from compensated hypertrophy
to heart failure in a murine model of systolic pressure over-
load, using W/c-kit mutant WBB6F1-W/W
 
v
 
 mice, in
which mast cells are nearly absent, and tranilast, a mast cell–
stabilizing agent.
 
Materials and Methods
 
All experiments were performed in 9-wk-old male mice, ob-
tained from Shizuoka Agricultural Cooperation Association, and
treated in accordance with local institutional guidelines at all
stages of the experiments.
 
Experiment 1.
 
Male W/W
 
v
 
 mice (
 
n
 
 
 
  
 
25), or their normal
male littermates, WBB6F1-
 
 
 
/
 
 
 
 (wild-type [WT]) mice (
 
n
 
 
 
 
 
24), were exposed to 15 wk of pressure overload produced by
banding of the abdominal aorta with minor modifications of a
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method described previously (8). The mice were anesthetized by
intraperitoneal injection of a mixture of ketamine, 100 mg/kg,
and xylazine, 5 mg/kg. The abdominal aorta was banded at the
suprarenal level with 5–0 silk suture material ligated around the
vessel and a 26-gauge needle, following which the needle was
withdrawn. In addition, 14 W/W
 
v
 
 mice and 11 WT mice under-
went identical surgical procedures, except for banding of the ab-
dominal aorta (sham-operated controls). At 4 wk after operation,
10 W/W
 
v
 
 mice and 10 WT mice were killed to examine the role
of mast cells in compensated hypertrophy. Thereafter, the re-
mainder of the mice were followed with serial echocardiography,
and killed at 15 wk to examine the role of mast cells in congestive
heart failure analyses.
 
Mast Cell Reconstitution of W/W
 
v
 
 Mice.
 
Mast cell reconstitution
of W/W
 
v
 
 mice was performed as described previously (9). Bone
marrow cells from femurs of male WT mice were cultured for 3
wk in WEHI-3 conditioned medium. To generate W/W
 
v
 
 
 
MC
mice, adoptive transfer of mast cells (
 
 
 
98% purity) into the hearts
of W/W
 
v
 
 mice was achieved by intravenous injection of 5 
 
  
 
10
 
6
 
mast cells, 2 d before aortic banding. The mice were killed 15 wk
after mast cell reconstitution and aortic banding. The density of
cardiac mast cells was confirmed by staining with toluidine
blue.
 
Bone Marrow Reconstitution of W/W
 
v
 
 Mice.
 
The bone marrow
reconstitution method has been described previously (10).
Briefly, WT mice were killed by cervical dislocation, and the
bone marrow was flushed with RPMI 1640 culture medium.
Bone marrow cells (3 
 
  
 
10
 
7
 
) were injected intravenously into
W/W
 
v
 
 mice 2 d before aortic banding. W/W
 
v
 
 mice with recon-
stituted bone marrow were killed 15 wk later. Hematocrit was
measured to confirm successful reconstitution.
 
Morphologic and Echocardiographic Studies.
 
After measurement
of their body mass, the animals were anesthetized with ketamine
(50 mg/kg) and xylazine (2.5 mg/kg). Transthoracic echocar-
diography was performed with a cardiac ultrasound recorder
(Toshiba Power Vision), using a 7.5-MHz transducer. After the
acquisition of high quality two-dimensional images, M-mode im-
ages of the left ventricle were recorded. Measurements of left
ventricular enddiastolic (LVDd) and endsystolic (LVDs) internal
dimensions were performed by the leading edge-to-leading edge
convention adopted by the American Society of Echocar-
diography. Percent fractional shortening (%FS) was calculated as
%FS 
 
  
 
([LVDd 
 
 
 
 LVDs]/LVDd) 
 
  
 
100.
 
Blood Pressure and Heart Rate Monitoring.
 
The hemodynamic
effects of aortic banding were monitored via the right carotid ar-
tery exposed through a cervical incision and isolated by blunt dis-
section as described by Rockman et al. (11). The lungs were
dried for 120 min at 60
 
 
 
C and weighed again. The lung water
content (LW) was calculated as LW 
 
  
 
lung weight (wet) 
 
 
 
 lung
weight (dry).
The pressure gradient across the aortic constriction was mea-
sured directly at 4 wk after operation with a 24 gauge polyethyl-
ene tube (TERUMO), inserted into the infrarenal abdominal
aorta, then advanced through the stenosis to measure blood pres-
sure at the suprarenal level. Pressure gradient was calculated as
(systolic blood pressure at the suprarenal level) 
 
 
 
 (systolic blood
pressure at the infrarenal level).
 
Histological Analysis.
 
We examined 15 banded W/W
 
v
 
 mice,
14 banded WT mice, 10 sham-operated W/W
 
v
 
 mice, and 9
sham-operated WT mice. The hearts were fixed with 10% for-
malin for histological examinations. The fixed hearts were im-
bedded in paraffin, sectioned in 2-
 
 
 
m thick slices, and stained
with hematoxylin-eosin for overall morphology, or with Sirius
 
red F3BA (0.1% solution in saturated aqueous picric acid) to al-
low a clear discrimination between cardiac myocytes and collagen
matrix (12). Changes in perivascular fibrosis were ascertained by
relating the area of perivascular fibrosis to the total vessel area as
described previously (13).
For transmission electron microscopy, heart specimens were
fixed with Karnovsky solution (3% glutaraldehyde and 1.6%
paraformaldehyde in 0.1 mol/liter phosphate buffer [PB], pH 7.4)
overnight at 4
 
 
 
C and then were cut into 1-mm thick sections.
They were postfixed in 1% osmium tetroxide in PB overnight at
4
 
 
 
C, dehydrated in ethanol series, and embedded in Polybed
(Polysciences Inc.). 70-nm thick ultrathin sections were stained
with saturated uranyl acetate and lead citrate, and observed under
a JEM-1200EX electron microscope (JEOL) at 100 kV.
 
Measurement of Plasma Angiotensin II Level and Renin Activity.
 
The abdomen of eight WBB6F1-W/W
 
v
 
 mice and seven WT
mice was opened under anesthesia with ketamine and xylazine
when killed at 15 wk after aortic banding. Blood was rapidly ob-
tained by puncture of the inferior vena cava, transferred to chilled
tubes containing aprotinin (1,000 kallidinogenase inactivator
units per milliliter) and Na
 
2
 
 EDTA (1 mg/ml), and immediately
centrifuged at 4
 
 
 
C. Plasma samples were stored at 
 
 
 
80
 
 
 
C until
angiotensin II measurement by ELISA. Plasma renin activity
(PRA) was determined using RENIN-RIABEAD (Dainabot).
 
Quantitative Reverse Transcription PCR Analysis.
 
We examined
five mice of each groups. Total RNA was isolated from the left
ventricle by the acid guanidinium thiocyanate-phenol-chloro-
form method. Real-time quantitative PCR (TaqMan PCR) us-
ing an ABI PRISM 7700 Sequence Detection System and Taq-
Man PCR Core Reagent Kit (PerkinElmer) was performed ac-
cording to the manufacturer’s protocol. 1 
 
 
 
l of the first strand
cDNA was used in the following assay. The following forward
(F) and reverse (R) oligonucleotides, and probes (P) were used
for the quantification of mouse mast cell protease (mMCP)-5,
atrial natriuretic peptide (ANP), angiotensinogen and GAPDH
mRNA; mMCP-5 F, 5
 
 
 
-TTGCCAGCCTGTGAGGAAA-3
 
 
 
;
mMCP-5 R, 5
 
 
 
-TACAGACAGGCCAGATCGCAT-3
 
 
 
;
mMCP-5 P, 5
 
 
 
-CTGGAACTGGAATAGTGCAGGTTTTGT-
GTG-3
 
 
 
: angiotensinogen F, 5
 
 
 
-TTGTCTAGGTTGGCGCT-
GAAG-3
 
 
 
; angiotensinogen R, 5
 
 
 
-AGATGCAGAAGATG-
GTGGCCT-3
 
 
 
; angiotensinogen P, 5
 
 
 
-ACACAGAAGCAA-
ATGCACAGATCGGAGA-3
 
 
 
: ANP F, 5
 
 
 
-CCATATTGGAG-
CAAATCCTGTG-3
 
 
 
; ANP R, 5
 
 
 
-CTTCTACCGGC-
CATCTTCTCCTC-3
 
 
 
; ANP P, 5
 
 
 
-TGATGGATTTCAA-
GAACCTGCTAGACCACC-3
 
 
 
: GAPDH F, 5
 
 
 
-TTCACC-
ACCATGGAGAAGGC-3
 
 
 
; GAPDH R, 5
 
 
 
-GGCATGGACT-
GTGGTCATGA-3
 
 
 
; GAPDH P, 5
 
 
 
-TGCATCCTGCACCAC-
CAACTGCTTAG-3
 
 
 
. The conditions for the TaqMan PCR
were as follows: 95
 
 
 
C for 10 min, followed by 40 cycles at 95
 
 
 
C
for 15 s and 60
 
 
 
C for 1 min.
 
Apoptosis Analysis.
 
We examined four banded W/W
 
v
 
 mice
and five banded WT mice. Apoptotic cells were identified by ter-
minal deoxynucleotidyl transferase UTP nick end labeling
(TUNEL) assay. Hearts were harvested 15 wk after operation
from banded and from sham-operated mice, fixed in 10% neutral
buffered formalin, and embedded in paraffin. Paraffin section,
2-
 
 
 
m thick, were mounted on slides, and apoptosis was detected
with an in situ Apoptosis Detection kit (Takara Shuzo Co.).
 
Experiment 2.
 
These experiments were performed in 9-wk-
old male C57BL/6 mice, because WT mice are semi-semisyn-
genic with C57BL/6 mice and the mice have been used to exam-
ine the effects of pressure overload in many previous reports.
Pressure overload was produced by banding of the abdominal 
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aorta as described earlier. 4 wk after surgery, the animals were
randomized to two groups. One group (
 
n
 
 
 
  
 
16) received tra-
nilast, (Kissei Pharmaceutical) 100 mg/kg, orally for 11 wk. The
other group (
 
n
 
 
 
  
 
20) received the vehicle for a same duration.
Echocardiography was performed 4 and 15 wk after operation,
and blood pressure was monitored at 15 wk as described above.
Mice were killed 15 wk after the operation, and their heart and
body weights were measured.
 
Statistical Analysis.
 
All results are expressed as mean 
 
 
 
 SEM.
Multiple comparisons among three or more groups were per-
formed by one-way analysis of variance (ANOVA) and Fisher’s
exact test for post hoc analysis. Differences were considered statis-
tically significant at 
 
P
 
 
 
  
 
0.05.
 
Results and Discussion
 
Experiment 1
Morphologic and Functional Effects of Pressure Overload.
 
At
4 wk, HW/BW was significantly greater in the animals
who had undergone aortic banding than in the sham-oper-
ated animals (
 
P
 
 
 
  
 
0.05), while no significant difference was
found between the two groups of mice exposed to pressure
overload (Table I). Likewise, echocardiographic left ven-
tricular performance was preserved and comparable in both
groups. No significant difference was measured between
the two groups in systolic blood pressure (114.0 
 
 
 
 4.1
mmHg in W/W
 
v
 
 mice, versus 120.1 
 
 
 
 7.8 mmHg in WT
mice) or in the systolic pressure gradient across the stenosis
(61.0 
 
 
 
 3.5 mmHg in W/W
 
v
 
 mice, versus 65.2 
 
 
 
 11.3
mmHg in WT mice). These results suggest that mast cells
play no role in compensated cardiac hypertrophy induced
by pressure overload.
However, clear differences in response to pressure over-
load became apparent at 15 wk (Table I). Although no sig-
nificant difference in systolic blood pressure was measured
between the W/W
 
v
 
 mice (114.8 
 
 
 
 7.2 mmHg) and the
WT mice (106.0   13.1 mmHg) who had undergone aor-
tic banding, mean HW/BW was significantly greater in
WT mice than in W/Wv mice. Table II presents the results
of the echocardiographic measurements performed at base-
line, and up to 15 wk after aortic banding in the W/Wv
versus the WT mice. Before, and within 8 wk of the oper-
ation, there was no significant difference in left ventricular
%FS, a measure of systolic function, between the two
groups. Whereas mean %FS remained in the range mea-
sured preoperatively up to 15 wk after aortic banding in the
W/Wv mice, it decreased significantly in the WT mice
(Table II). In contrast to the WT mice, whose left ventric-
ular dimensions increased significantly between baseline
and 15 wk, the W/Wv mice had no apparent loss of systolic
function (Table II). Lung weight and lung water content,
corrected for body weight, were higher in WT mice than
in W/Wv mice and in sham-operated mice (Table I).
These observations suggest that loss of myocardial function
was confined to the WT mice exposed to pressure over-
load. In summary, chronic pressure overload caused the de-
terioration of left ventricular performance, pulmonary con-
gestion, and maladaptive hypertrophy in WT mice, while
overall cardiac function remained stable in W/Wv mice.
These results indicate that mast cells have a key role in the
evolution from compensated to decompensated hypertro-
phy in pressure overloaded mice.
Histological Study. A prominent increase in perivascular
fibrosis was observed only in WT mice, whereas in W/Wv
mice, its extent was nearly the same as that in sham-oper-
ated mice (Fig. 1, A and B). In addition, there was a trend
toward a lesser amount of interstitial fibrosis in W/Wv
compared with WT mice. Likewise, TUNEL assay re-
vealed more apoptotic cardiac myocytes in WT mice than
in W/Wv mice, although the difference was not statistically
significant. An attempt was made to identify apoptotic car-
diac myocytes by transmission electron microscopic analy-
sis, the confirmatory gold standard of the presence of apop-
Table I. Morphometric and Hemodynamic Analysis
Preband 4 wk 15 wk
W/Wv WT W/Wv WT W/Wv WT
n 5 5 9 6 12 13
BW (g) 26.3   0.2 28.1   0.5a 26.6   0.4 27.9   0.4a 30.6   0.5 33.9   0.5a
HW (mg) 114.7   1.5 121.4   1.5a 158.4   11.2 171.6   11.4 146.2   5.4 220.5   20.1a
Lung (wet) (mg) 139.1   3.2 160.6   3.2a ND ND 155.9   3.6 215.4   12.9a
LW (mg) 107.7   3.0 124.1   3.7a ND ND 122.7   3.6 171.3   14.8a
HW/BW (mg/g) 4.37   0.07 4.32   0.05 5.94   0.38 6.17   0.43 4.77   0.12 6.53   0.67a
Lung/BW (mg/g) 5.31   0.09 5.89   0.11a ND ND 5.10   0.06 6.39   0.66a
LW/BW (mg/g) 4.11   0.09 4.55   013a ND ND 4.1   0.07 5.09   0.51a
Syst. BP (mmHg) ND ND 130.4   5.3 135.3   10.8 114.8   7.2 106.0   13.1
BW, body weight; HW, heart weight; LW, lung water; Syst. BP, systolic blood pressure; ND, not done.
aP   0.05 for W/Wv versus WT.378 Mast Cells in Heart Failure
tosis. However, no apoptotic myocytes were found,
probably because of their low density in our experimental
model. However, a decrease in myofilamments, mitochon-
drial degeneration, and accumulation of lipid droplets were
observed in WT mice (Fig. 1 C). These were rarely found
in W/Wv mice.
The number of mast cells, at 15 wk, was significantly
greater in the hearts of banded (12.2   1.7 mast cells/
slice) than of sham-operated (5.5   1.3 mast cells/slice)
WT mice (P   0.0001). Mast cells were not detectable in
W/Wv mice.
Expression of Chymase Gene. As we had previously hy-
pothesized that mast cell chymase plays a role in the patho-
physiology of heart failure (7), we examined the upregula-
tion of mMCP-5, the counterpart of human chymase. The
evolution of the relative levels of mMCP-5 is shown in
Fig. 2 A. The gene expression levels of mMCP-5 after aor-
tic banding were significantly higher in WT mice than in
W/Wv mice.
Effects of Angiotensin II. No significant difference was
found in mean plasma angiotensin II level between W/Wv
mice (217.3   66.7 pg/ml) and WT mice (249.1   63.7
pg/ml) exposed to pressure overload (Fig. 2 B). Likewise,
the gene expression levels of angiotensinogen in the hearts
were comparable among all study groups (Fig. 2 C).
Plasma renin activity (PRA) in mast cell deficient W/Wv
mice (9-wk-old, n   3) or WT mice (9-wk-old, n   3)
was also measured. PRA was 1.0   0.47 ng/ml/h in W/Wv
mice, versus 0.89   0.43 ng/ml/h in WT mice, a non-
significant difference.
Effects of Chronic Pressure Overload on Fetal Gene Expres-
sion. We had verified that, in our experimental models,
mRNA levels of ANP were increased 4 wk after aortic
banding (data not shown). At 15 wk after operation, ANP
mRNA levels were increased in banded mice, and they
were higher in WT mice than in W/Wv mice (Fig. 2 D).
Reconstitution of Mast Cells and Bone Marrow Cells. Car-
diac mast cells were not reconstituted by the transfusion of
bone marrow–derived mast cells or bone marrow cells, al-
though mast cells were reconstituted in other murine tis-
sues, such as lungs. Consequently, we could not verify the
Table II. Echocardiographic Measures in Preband and Postband Mice
Preband 8 wk 11 wk 15 wk
W/Wv WT W/Wv WT W/Wv WT W/Wv WT
LVDd (mm) 2.96   0.12 2.86   0.09 3.08   0.17 3.40   0.14 3.12   0.11 3.52   0.10 3.02   0.17 3.60   0.19a
LVDs (mm) 0.80   0.04 0.80   0.03 0.73   0.11 0.99   0.09 0.89   0.08 1.35   0.17a 0.77   0.08 1.85   0.27a
%FS 72.8   1.8 71.9   1.5 77.2   2.5 71.2   1.9 71.6   2.0 62.2   4.1a 75.1   1.8 50.6   4.8a
LVDd, end-diastolic left ventricular internal dimension; LVDs, end-systolic left ventricular internal dimension; %FS, left ventricular percent fractional
shortening.
aP   0.05 for W/Wv versus WT.
Figure 1. Microscopic analysis at 15 wk after aortic banding. (A) Rela-
tive area of fibrosis. Values are mean   SEM. *P   0.05 vs. W/Wv mice
and sham operated mice. (B) Histological staining of left ventricular fibro-
sis (Sirius red). Perivascular collagen accumulation (red) is more promi-
nent in WT hypertensive mouse. Original magnification,  200.   ,
banded mice;  , sham-operated mice. (C) Transmission electron micros-
copy. In WT mice (left panel), clusters of mitochondria (mit) of various
shape and size were noted. A decrease in the density of myofibrils is also
apparent. Original magnification,  5,000. Bar, 5  m.379 Hara et al. Brief Definitive Report
roles played by mast cells by their reconstitution. Reconsti-
tution of bone marrow cells mitigated the anemia; hemat-
ocrit was 28   2.6% in W/Wv mice (24-wk-old, n   4),
versus 34   0.9% in W/Wv mice (24-wk-old, n   5) with
reconstituted bone marrow cells. However, maladaptive
cardiac hypertrophy or decreased cardiac systolic function
were observed neither in W/Wv mice nor in W/Wv mice
with reconstituted bone marrow cells. This suggests that
anemia was not the reason for the absence of heart failure
progression in W/Wv mice.
Experiment 2
Effects of Tranilast on Cardiac Dimensions and Function.
The mutation of W/c-kit produces receptors with mark-
edly deficient tyrosine kinase activity, resulting not only in
mast cell deficiency but also in anemia, lack of melanocytes
in the skin, and sterility (14). The degree of anemia in mast
cell deficient W/Wv mice (9-wk-old, n   3) or WT mice
(9-wk-old, n   3), unexposed to pressure overload, was
examined. Hematocrit was 37.9   1.3% in W/Wv mice,
versus 53.3   1.2% in WT mice, and hemoglobin concen-
tration was 10.2   0.8 g/dl in W/Wv mice, versus 14.6  
0.3 g/dl in WT mice. To further examine the role of mast
cells in the progression of heart failure, the effects of tra-
nilast, a mast cell stabilizer, were studied in 9-wk-old male
C57BL/6 mice. Baseline echocardiograms confirmed com-
parable left ventricular dimensions and systolic function in
the tranilast- versus the vehicle-treated groups. At 15 wk
after aortic banding, no significant difference was measured
in systolic blood pressure between the tranilast-treated and
the control groups (Fig. 3 A). However, treatment with
tranilast significantly limited the development of cardiac
hypertrophy (Fig. 3 B), fall in %FS (Fig. 3 C), and left ven-
tricular chamber dilatation (Fig. 3 D). Combined with the
results of experiment 1, these observations suggest that mast
cells amplify the pathophysiologic manifestations of heart
failure in pressure-overloaded mice.
This study showed that a mutation at the W/c-kit locus,
and treatment with tranilast prevented the evolution from
compensated hypertrophy to heart failure in a murine
Figure 2. Real-time quantitative PCR analysis and
angiotensin II concentrations in plasma. (A) mRNA
levels of mMCP-5. (B) Angiotensin II concentrations
in plasma. (C) mRNA levels of angiotensinogen in the
hearts. (D) mRNA levels of ANP.  , banded mice;  ,
sham-operated mice. Values represent the normalized
mean   SEM. *P   0.05.
Figure 3. Effects of tranilast on blood pressure, heart weight and
echocardiographic measurements. (A) Arterial blood pressure. (B) Heart
weight (mg)/body weight (g) ratio. (C) Left ventricular percent fractional
shortening (FS). (D) Left ventricular dimensions. Dd, enddiastolic diame-
ter; Ds, endsystolic diameter. Values are mean   SEM. *P   0.05.  ,
banded mice;  , sham-operated mice.380 Mast Cells in Heart Failure
model of systolic pressure overload. This is the first in vivo
demonstration of a direct contribution of W/c-kit in the
pathogenesis of heart failure, and our results strongly impli-
cate mast cells in this process.
Our experiments showed that mast cell deficiency atten-
uated the development of myocardial fibrosis and systolic
pressure overload-induced hypertrophy. As each of these
processes is likely to cause cardiac dysfunction, the mecha-
nisms by which mast cells promote heart failure should be
discussed in light of them. First, myocardial fibrosis induced
by mast cells may impair diastolic function. In this study,
perivascular fibrosis was prominent in WT mice, but not in
W/Wv mice. This indicates that mast cells play a role in the
development of myocardial fibrosis found in pressure-over-
loaded hearts. It has been reported that the number of mast
cells is increased in fibrotic diseases of skin (15) and lung.
Mast cells have also been found to induce proliferation of
fibroblasts by various mediators in vitro, such as chymase
(7), histamine, and tryptase (16). Patella et al. have recently
described an increase in mast cells in the hearts of dilated
and ischemic cardiomyopathy (6), where fibrosis is promi-
nent. Consequently, it appears very likely that mast cells in-
duce myocardial fibrosis as part of the development of heart
failure. Second, mast cells may promote cardiac maladap-
tive hypertrophy. At 15 wk, the W/Wv mice had mild
concentric left ventricular hypertrophy with preserved sys-
tolic function. In contrast, marked cardiac hypertrophy and
ventricular dilatation with reduced %FS were observed in
the WT mice, suggesting that mast cells promote maladap-
tive hypertrophy, ventricular dilatation, and cardiac de-
compensation. These cardiac changes may be caused by
bioactive peptides such as angiotensin II and endothelin 1,
also known to induce hypertrophy of cardiac myocytes and
myocardial fibrosis. However, the involvement of angio-
tensin II was not clarified in our study. Endothelin 1 is an-
other potent mediator, which can induce hypertrophy of
cardiac myocytes and proliferation of cardiac fibroblasts.
Mast cell chymase is reported to activate big endothelin to
endothelin 1 (17). We have previously reported that mast
cell chymase induces apoptosis of cardiac myocytes in vitro
(7). In addition, chymase has been implicated in tissue re-
modeling through activation of matrix metalloproteinases
(18) and IL-1  precursors (19), and proliferation of fibro-
blasts (7). These observations suggest that the modulation
of tissue remodeling by chymase was one of the mecha-
nisms of heart failure progression in our study.
Other mediators contained in mast cell granules, such as
tryptase and cytokines, might play a role in cardiac changes
caused by systolic pressure overload (20). We do not ex-
clude the possibility that maladaptive hypertrophy was
partly induced by a direct interaction between stem cell
factor and c-kit. The undefined role of stem cell factor in
cardiovascular diseases is in need of further research.
The number of mast cells and mMCP-5 mRNA level,
major mediator of mast cells, were significantly greater in
banded WT mice than in sham-operated mice. This sug-
gests that mast cells are upregulated in pressure overloaded
mice.
Tranilast, N-(3,4-dimethoxycinnamoyl) anthranillic acid,
is an oral antiallergic drug used in Japan. Its antiallergic ef-
fects are mainly mediated by the inhibition of the release of
chemical mediators from mast cells. It has been described as
effective in the prevention of coronary restenosis after di-
rectional coronary atherectomy in humans (21), and in the
suppression of neointima formation in balloon-injured dog
carotid artery (22). Furthermore, tranilast suppresses the
vascular expression of chymase (22). Therefore, we hy-
pothesize that the effects of tranilast in the prevention of
heart failure in our study were mainly due to the suppres-
sion of mast cell degranulation and inhibition of mast cell
chymase.
In conclusion, we present several lines of evidence indi-
cating that mast cells play a role in the evolution from
compensated hypertrophy to congestive heart failure. As
mast cell stabilizers, including tranilast, are safely used as an-
tiallergic agents in Japan, we are planning to examine
whether they may be a new option in the management of
heart failure.
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